202 related articles for article (PubMed ID: 26376615)
1. Targeting Batf2 for infectious diseases and cancer.
Guler R; Roy S; Suzuki H; Brombacher F
Oncotarget; 2015 Sep; 6(29):26575-82. PubMed ID: 26376615
[TBL] [Abstract][Full Text] [Related]
2. Batf2/Irf1 induces inflammatory responses in classically activated macrophages, lipopolysaccharides, and mycobacterial infection.
Roy S; Guler R; Parihar SP; Schmeier S; Kaczkowski B; Nishimura H; Shin JW; Negishi Y; Ozturk M; Hurdayal R; Kubosaki A; Kimura Y; de Hoon MJ; Hayashizaki Y; Brombacher F; Suzuki H
J Immunol; 2015 Jun; 194(12):6035-44. PubMed ID: 25957166
[TBL] [Abstract][Full Text] [Related]
3. Compensatory dendritic cell development mediated by BATF-IRF interactions.
Tussiwand R; Lee WL; Murphy TL; Mashayekhi M; KC W; Albring JC; Satpathy AT; Rotondo JA; Edelson BT; Kretzer NM; Wu X; Weiss LA; Glasmacher E; Li P; Liao W; Behnke M; Lam SS; Aurthur CT; Leonard WJ; Singh H; Stallings CL; Sibley LD; Schreiber RD; Murphy KM
Nature; 2012 Oct; 490(7421):502-7. PubMed ID: 22992524
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effect of
Kanemaru H; Yamane F; Fukushima K; Matsuki T; Kawasaki T; Ebina I; Kuniyoshi K; Tanaka H; Maruyama K; Maeda K; Satoh T; Akira S
Proc Natl Acad Sci U S A; 2017 Aug; 114(35):E7331-E7340. PubMed ID: 28808017
[TBL] [Abstract][Full Text] [Related]
5. Quantitative profiling of BATF family proteins/JUNB/IRF hetero-trimers using Spec-seq.
Chang YK; Zuo Z; Stormo GD
BMC Mol Biol; 2018 Mar; 19(1):5. PubMed ID: 29587652
[TBL] [Abstract][Full Text] [Related]
6. BATF2 inhibits chemotherapy resistance by suppressing AP-1 in vincristine-resistant gastric cancer cells.
Yang W; Zhao S; Wu B; Xu J; Wu Z; Guo J; Zeng R
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1279-1288. PubMed ID: 31549215
[TBL] [Abstract][Full Text] [Related]
7. Batf2 differentially regulates tissue immunopathology in Type 1 and Type 2 diseases.
Guler R; Mpotje T; Ozturk M; Nono JK; Parihar SP; Chia JE; Abdel Aziz N; Hlaka L; Kumar S; Roy S; Penn-Nicholson A; Hanekom WA; Zak DE; Scriba TJ; Suzuki H; Brombacher F
Mucosal Immunol; 2019 Mar; 12(2):390-402. PubMed ID: 30542107
[TBL] [Abstract][Full Text] [Related]
8. m
Xie JW; Huang XB; Chen QY; Ma YB; Zhao YJ; Liu LC; Wang JB; Lin JX; Lu J; Cao LL; Lin M; Tu RH; Zheng CH; Huang CM; Li P
Mol Cancer; 2020 Jul; 19(1):114. PubMed ID: 32650804
[TBL] [Abstract][Full Text] [Related]
9. Expression and clinical implications of basic leucine zipper ATF-like transcription factor 2 in breast cancer.
Lin Y; Zhou X; Peng W; Wu J; Wu X; Chen Y; Cui Z
BMC Cancer; 2021 Sep; 21(1):1062. PubMed ID: 34565331
[TBL] [Abstract][Full Text] [Related]
10. BATF2 prevents T-cell-mediated intestinal inflammation through regulation of the IL-23/IL-17 pathway.
Kayama H; Tani H; Kitada S; Opasawatchai A; Okumura R; Motooka D; Nakamura S; Takeda K
Int Immunol; 2019 May; 31(6):371-383. PubMed ID: 30753547
[TBL] [Abstract][Full Text] [Related]
11. Specificity through cooperation: BATF-IRF interactions control immune-regulatory networks.
Murphy TL; Tussiwand R; Murphy KM
Nat Rev Immunol; 2013 Jul; 13(7):499-509. PubMed ID: 23787991
[TBL] [Abstract][Full Text] [Related]
12. BATF2 reverses multidrug resistance of human gastric cancer cells by suppressing Wnt/β-catenin signaling.
Yang W; Wu B; Ma N; Wang Y; Guo J; Zhu J; Zhao S
In Vitro Cell Dev Biol Anim; 2019 Jun; 55(6):445-452. PubMed ID: 31140101
[TBL] [Abstract][Full Text] [Related]
13. Decreased expression of BATF2 is significantly associated with poor prognosis in oral tongue squamous cell carcinoma.
Wen H; Chen Y; Hu Z; Mo Q; Tang J; Sun C
Oncol Rep; 2014 Jan; 31(1):169-74. PubMed ID: 24252932
[TBL] [Abstract][Full Text] [Related]
14. The role of BATF2 deficiency in immune microenvironment rearrangement in cervical cancer - New biomarker benefiting from combination of radiotherapy and immunotherapy.
Zong Y; Chang Y; Huang K; Liu J; Zhao Y
Int Immunopharmacol; 2024 Jan; 126():111199. PubMed ID: 37995570
[TBL] [Abstract][Full Text] [Related]
15. "Tuberculosis in advanced HIV infection is associated with increased expression of IFNγ and its downstream targets".
Verma S; Du P; Nakanjako D; Hermans S; Briggs J; Nakiyingi L; Ellner JJ; Manabe YC; Salgame P
BMC Infect Dis; 2018 May; 18(1):220. PubMed ID: 29764370
[TBL] [Abstract][Full Text] [Related]
16. BATF2 prevents glioblastoma multiforme progression by inhibiting recruitment of myeloid-derived suppressor cells.
Zhang X; Liu Y; Dai L; Shi G; Deng J; Luo Q; Xie Q; Cheng L; Li C; Lin Y; Wang Q; Fan P; Zhang H; Su X; Zhang S; Yang Y; Hu X; Gong Q; Yu D; Zheng L; Deng H
Oncogene; 2021 Feb; 40(8):1516-1530. PubMed ID: 33452462
[TBL] [Abstract][Full Text] [Related]
17. The tumor-suppressive role of BATF2 in esophageal squamous cell carcinoma.
Han T; Wang Z; Yang Y; Shu T; Li W; Liu D; Li P; Qi R; Ren Y; Li L; Liu H; Zhang S; Zhang L
Oncol Rep; 2015 Sep; 34(3):1353-60. PubMed ID: 26135942
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a Regulatory Motif for Human Satellite DNA Transcription in Response to BATF2 Overexpression.
Bai X; Huang W; Zhang C; Niu J; Ding W
Anticancer Res; 2016 Mar; 36(3):1203-10. PubMed ID: 26977016
[TBL] [Abstract][Full Text] [Related]
19. BATF and BATF3 deficiency alters CD8+ effector/exhausted T cells balance in skin transplantation.
Li C; Liu Z; Wang Z; Yim WY; Huang Y; Chen Y
Mol Med; 2024 Jan; 30(1):16. PubMed ID: 38297190
[TBL] [Abstract][Full Text] [Related]
20. Decreased expression of BATF2 is associated with a poor prognosis in hepatocellular carcinoma.
Ma H; Liang X; Chen Y; Pan K; Sun J; Wang H; Wang Q; Li Y; Zhao J; Li J; Chen M; Xia J
Int J Cancer; 2011 Feb; 128(4):771-7. PubMed ID: 20473897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
